Empower & Confirm Diagnosis

Practices are evolving—not only to meet the challenges of resistant head lice, but in response to changing healthcare dynamics. As a complete solution, Natroba™ (spinosad) can help.

Head Lice Assessment Videos

Permethrin- and pyrethrin-resistance is seen here in live head lice 15 minutes after treatment with Nix®, as compared to an untreated control group.1

  • Compare these in vitro videos against patient-provided images or video to confirm your diagnosis
  • Share these videos with patients as an online teaching tool
 

Untreated Lice

 

Treated with Nix®

Source: Videos created in collaboration with J. Marshall Clark, et. al, and the Departments of Veterinary and Animal Sciences, Molecular Pharmacology, Microbiology, and Biochemistry and Molecular Biology at the University of Massachusetts, Amherst.

Pediatric Telehealth Directory

Are you available to your patients by phone or video conference to confirm a head lice diagnosis? Join our searchable directory of pediatric practices offering telehealth services—and help more patients find you.

White iPhone
Join our directory

Avoid OTC Resistance

Today, head lice resistance to permethrin- and pyrethrin-based OTC products is >98% across 48 states. The most significant contributors to increasing resistance include misdiagnosis and overuse of OTC pediculicides.1,2,3

 

The Facts About Head Lice Resistance Are Irrefutable

Important Safety Information

Indication
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Natroba™ Topical Suspension should be used in the context of an overall lice management program:
• Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
• Wash personal care items such as combs, brushes, and hair clips in hot water
• A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Important Safety Information
Natroba™ Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Nix® is a registered trademark of Prestige Consumer Healthcare Inc.

Reference(s)
  1. Gellatly KJ, Krim S,Palenchar DJ, et al. Expansion of the knockdown resistance frequency map for human head lice (phthiraptera: pediculidae) in the United States using quantitative sequencing. Journal of Medical Entomology, 2016:1-7
  2. Meinking TL, Serrano L, Hr B, et al. Comparative in vitro pediculicidal efficacy of treatments in a resistant head lice population in the United States. Arch Dermatol. 2002; 138:220-224
  3. DP West, Head Lice Treatment Costs and the Impact on Managed Care, Amer J of Managed Care, September 1, 2004

NAT-RRW2-001

Important Safety Information

Indication
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Natroba™ Topical Suspension should be used in the context of an overall lice management program:
• Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
• Wash personal care items such as combs, brushes, and hair clips in hot water
• A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Important Safety Information
Natroba™ Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.